Financial Data and Key Metrics Changes - The company has sufficient cash to complete its trials, with an expected cash runway extending into 2028, indicating no immediate financial overhang [8] Business Line Data and Key Metrics Changes - The lead compound, ABTX009, is currently in Phase 2b of the LOTUS trial, with results expected in mid-2026 [7] - The company is targeting hidradenitis suppurativa (HS), a severe skin disease, with a significant unmet medical need [5][12] Market Data and Key Metrics Changes - The HS market is evolving, with new therapies emerging, but there remains a substantial unmet need for more effective treatments [11][12] - The market for HS is projected to grow significantly, with conservative estimates suggesting it could reach $10 billion by 2035 [42] Company Strategy and Development Direction - The company aims to transition rapidly into Phase 3 trials following the Phase 2 results, with a potential BLA filing anticipated around 2029 [34] - The strategy includes differentiating ABTX009 from competitors by focusing on its higher potency and longer half-life compared to existing therapies [6][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the mechanism of action of ABTX009, highlighting its potential to treat additional immune-mediated inflammatory diseases [8] - The management noted that dermatologists are increasingly looking for new therapies due to the limitations of current treatments, indicating a favorable environment for new entrants [35][38] Other Important Information - The trial design for ABTX009 is similar to that of other recent studies, with a focus on clinically relevant endpoints [27] - The company is studying a diverse patient demographic across the US, Canada, Australia, and Europe, which may help in achieving robust treatment effects [31] Q&A Session Summary Question: Can you discuss the current state of HS and the effectiveness of emerging therapies? - Management highlighted that HS is a severe disease with significant pain and disability, and there is a growing recognition of the need for better therapies [11] Question: What differentiates ABTX009 from other IL-1 strategies? - Management emphasized that targeting IL-1 beta specifically is advantageous, as it plays a pivotal role in chronic inflammation associated with HS [20][21] Question: What are the expectations for the Phase 2 trial data readout in 2026? - The study is powered to show a placebo-subtracted efficacy rate of 25-30%, with a robust treatment effect expected [28][30] Question: How does the company plan to carve out a commercial niche in the HS market? - Management believes that with a differentiated side effect profile and superior efficacy, ABTX009 can capture a significant share of the market [39][42] Question: What are the potential additional indications for IL-1 beta? - Management mentioned several potential indications, including Crohn's disease and rheumatoid arthritis, highlighting the broad applicability of IL-1 beta targeting [43][44]

Investor Presentation NYSE: IDT Third Quarter Fiscal 2025 June 2025 ForwýrĀ-Looking Stýtāmānts All statements in this presentation that are not purely about historical facts, including, but not limited to, those in which we use the words "believe," "anticipate," "expect," "plan," "intend," "estimate, "target" and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment ...

Investor Presentation As of March 31, 2025 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of Washington Federal's management and are subject to significant risks and uncertainties. The forward-looking statements in this presentation speak only as of the date of the presentation, and Washington Federal assumes no duty, and does not undertake, to update them. A ...

LANVIN GROUP 2023 FULL-YEAR RESULTS April 30, 2024 DISCLAIMER Forward-Looking Statements This presentation ...

August 26, 2024 Forward-Looking Statements This presentation, including the sections "2024 First Half Achievements", "2024 Outlook", "Brand-Level Performance" and "Appendix", contain "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," ...

April 30, 2025 Forward-Looking Statements This presentation, including the sections "2025 GUIDANCE", "BRAND-LEVEL PERFORMANCE" and "APPENDIX", contain "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "fu ...

May 2025 THE PRESENTATION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED TO BE, AND SHALL NOT BE CONSTRUED AS, AN ADVERTISEMENT, OFFER, SOLICITATION OR INVITATION, OR FORM PART OF AN ADVERTISEMENT, OFFER, SOLICITATION OR INVITATION, TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES, AND NEITHER THE PRESENTATION NOR ANYTHING CONTAINED IN THE PRESENTATION SHALL FORM THE BASIS OF OR BE RELIED UPON IN CONNECTION WITH ANY CONTRACT OR COMMITMENT WHATSOEVER. In particular, this presentation does not constitute a ...

MongoDB (MDB) FY 2025 Annual General Meeting June 30, 2025 10:00 AM ET Speaker0 Good morning, and welcome to MongoDB's twenty twenty five Annual Meeting of Stockholders. I would now like to turn the meeting over to Dave Itacharya, MongoDB's President and Chief Executive Officer. Speaker1 Good morning, and welcome to MongoDB's Annual Meeting of Stockholders. Thank you for joining us today. I am Dev Vitticharya, President and Chief Executive Officer of MongoDB and a member of the Board of Directors. Before I ...

Fourth Quarter and Full Year 2014 Earnings Conference Call February 24, 2015 Agenda | Introduction | Leah Stearns | | --- | --- | | | Senior Vice President, Treasurer and Investor Relations | | Opening Remarks | Jim Taiclet | | | Chairman, President and Chief Executive Officer | | Financial Results | Tom Bartlett | | | Executive Vice President, Chief Financial Officer | | Q&A | | 2 Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This presentatio ...

Fourth Quarter and Full Year 2015 Earnings Conference Call February 26, 2016 Agenda | Introduction | Leah Stearns | | --- | --- | | | Senior Vice President, Treasurer and Investor Relations | | Strategic Update | Jim Taiclet | | | Chairman, President and Chief Executive Officer | | Financial Results | Tom Bartlett | | | Executive Vice President, Chief Financial Officer | | Q&A | | 2 Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This presentati ...